HC Wainwright Brokers Reduce Earnings Estimates for TSE:ONC

Oncolytics Biotech Inc. (TSE:ONC) – Analysts at HC Wainwright decreased their FY2030 earnings per share estimates for shares of Oncolytics Biotech in a report issued on Wednesday, August 19th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of $0.10 per share for the year, down from their prior forecast of $0.19. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Oncolytics Biotech Stock Down 1.3%

Shares of ONC opened at C$14.90 on Thursday. The company has a debt-to-equity ratio of 14.58, a current ratio of 2.88 and a quick ratio of 8.86. The stock has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. Oncolytics Biotech has a 1 year low of C$0.44 and a 1 year high of C$2.08. The business’s 50 day simple moving average is C$14.90 and its 200-day simple moving average is C$14.90.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.